Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Melanoma

Complete title: A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients with Advanced Solid Tumors: Melanoma, Renal Cell, Sarcoma, Colon, Non-Hodgkin Lymphoma, Non-Small Cell Lung, Squamous Cell Head and Neck Cancer and Cutaneous Squamous Cell Cancer

Research Study Number 9103A
Principal Investigator Sylvia Lee, MD
Phase I

Research Study Description

The proposed clinical trial is a phase I, open-label, multi-center, dose-escalation study of ALT-803 in patients with surgically incurable advanced melanoma.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 9103A
Contact Kelly Yim
Telephone 206/288-7370

Keywords: Melanoma; Solid Tumors; Neuroendocrine Tumor; Immunotherapy

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials